Literature DB >> 31845119

Clinical significance of preoperative serum concentrations of interleukin-6 as a prognostic marker in patients with esophageal cancer.

Yusuke Maeda1, Hiroya Takeuchi2, Satoru Matsuda1, Akihiko Okamura1, Kazumasa Fukuda1, Taku Miyasho3, Rieko Nakamura1, Koichi Suda1, Norihito Wada1, Hirofumi Kawakubo1, Yuko Kitagawa1.   

Abstract

BACKGROUND: Although the clinical outcome of esophageal cancer has recently improved, the relapse rate remains high for all disease stages. At present, there is no diagnostic method to predict the long-term outcome for esophageal cancer. In this study, we evaluated serum preoperative proinflammatory cytokine levels and investigated the correlation between preoperative interleukin-6 (IL-6) and IL-8 levels and survival of patients with esophageal cancer.
METHODS: Between 2008 and 2015, we evaluated preoperative serum cytokine levels in 122 patients who underwent esophagectomy for esophageal cancer. Serum IL-6 and IL-8 levels were measured by enzyme-linked immunosorbent assays. We investigated the relationship between serum cytokine levels and the response to chemotherapy and survival.
RESULTS: The preoperative IL-6 levels were significantly associated with shorter recurrence-free survival (RFS, p = 0.001) and overall survival (OS, p = 0.001) after esophagectomy. Higher IL-8 levels were significantly associated with RFS (p = 0.018). In the multivariate analysis, age, preoperative chemotherapy, lymph node metastasis, serum C-reactive protein (CRP) levels and serum IL-6 levels (hazard ratio (HR), 2.888; p = 0.049) were significantly independent prognostic factors of RFS. Additionally, age, pathological stage, and serum IL-6 levels (HR, 3.247; p = 0.027) were shown to be significantly independent prognostic factors of OS. Serum IL-6 levels were significantly higher in the non-responder group (pathological response pGrade0 and pGrade1) after neoadjuvant therapy.
CONCLUSIONS: High preoperative serum IL-6 levels are associated with a poor response to chemotherapy or chemoradiotherapy and poor prognosis after esophagectomy. Preoperative serum IL-6 levels may be a useful independent prognostic marker for esophageal cancer patients.

Entities:  

Keywords:  Esophageal cancer; Esophagectomy; Interleukin-6

Mesh:

Substances:

Year:  2019        PMID: 31845119     DOI: 10.1007/s10388-019-00708-6

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  5 in total

1.  Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma.

Authors:  Wenhu Liu; Qiang Wang; Jinxia Chang; Anup Bhetuwal; Nisha Bhattarai; Fan Zhang; Jiancai Tang
Journal:  Clin Proteomics       Date:  2022-05-24       Impact factor: 5.000

2.  Validation Study of Fibrinogen and Albumin Score in Esophageal Cancer Patients Who Underwent Esophagectomy: Multicenter Prospective Cohort Study.

Authors:  Satoru Matsuda; Hiroya Takeuchi; Hirofumi Kawakubo; Ryo Takemura; Yusuke Maeda; Yuki Hirata; Takuji Kaburagi; Tomohisa Egawa; Tomohiko Nishi; Masaharu Ogura; Taku Miyasho; Akihiko Okamura; Shuhei Mayanagi; Kazumasa Fukuda; Rieko Nakamura; Tomoyuki Irino; Norihito Wada; Yuko Kitagawa
Journal:  Ann Surg Oncol       Date:  2020-07-31       Impact factor: 5.344

Review 3.  The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs).

Authors:  Payam Behzadi; Aga Syed Sameer; Saniya Nissar; Mujeeb Zafar Banday; Márió Gajdács; Herney Andrés García-Perdomo; Kulsum Akhtar; Marina Pinheiro; Peter Magnusson; Meysam Sarshar; Cecilia Ambrosi
Journal:  J Immunol Res       Date:  2022-03-26       Impact factor: 4.818

Review 4.  Cytokine Interaction With Cancer-Associated Fibroblasts in Esophageal Cancer.

Authors:  Md Sazzad Hassan; Nicholas Cwidak; Niranjan Awasthi; Urs von Holzen
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

Review 5.  Potential mechanisms of tumor progression associated with postoperative infectious complications.

Authors:  Hironori Tsujimoto; Minako Kobayashi; Hidekazu Sugasawa; Satoshi Ono; Yoji Kishi; Hideki Ueno
Journal:  Cancer Metastasis Rev       Date:  2021-01-03       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.